BoeijingaPHParotPSouffletL (2004) Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology50: 71–77.
2.
ChickJLehertPLandronF (2003) Does acamprosate improve reduction of drinking as well as aiding abstinence?J Psychopharmacol17: 387–392.
3.
ChickJNuttDJ (2011) Substitution therapy for alcoholism: time for a reappraisal?J Psychopharmacol26: 204–211.
4.
CrunelleCLMillerMLBooijJvan den BrinkW (2010) The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol20: 69–79.
5.
FranklinTRHarperDKampmanKKildea-McCreaSJensWLynchKGO’BrienCPChildressAR (2009) The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend103: 30–36.
6.
GrantJEKimSWHartmanBK (2008) A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry69: 783–789.
7.
JohnsonBARosenthalNCapeceJATopiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA298: 1641–1651.
8.
KranzlerHRTennenHArmeliSChanGCovaultJAriasA. (2009) Targeted naltrexone for problem drinkers. J Clin Psychopharmacol29: 350–357.
9.
KarhuvaaraSSimojokiKVirtaARosbergMLöyttyniemiENurminenT. (2007) Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res31: 1179–1187.
10.
LeggioLGarbuttJCAddoloratoG (2010) Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets9: 33–44.
11.
Lingford-HughesARWelchSNuttDJBritish Association for Psychopharmacology (2004) Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol18: 293–335.
12.
Lingford-HughesAWatsonBKalkNReidA (2010) Neuropharmacology of addiction and how it informs treatment. Br Med Bull96: 93–110.
13.
MannKKieferFSpanagelRLittletonJ (2008) Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res32: 1105–1110.
14.
NICE (2011) Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence NICE clinical guideline 115. London: National Institute for Health and Clinical Excellence.
15.
NuttDJ (2003) Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol17: 355–364.
16.
NuttDJ (2010) Antagonist-agonist combinations as therapies for heroin addiction: back to the future?J Psychopharmacol24: 141–145.
17.
O’MalleySSJaffeAJChangG. (1992) Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry49: 881–7.
18.
RösnerSLeuchtSLehertPSoykaM (2008) Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol22: 11–23.
19.
VolpicelliJRAltermanAIHayashidaM. (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry49: 876–80.
